Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by Lynx9on Feb 04, 2020 12:21pm
113 Views
Post# 30640388

RE:RE:RE:RE:RE:RE:Sachs Presentation

RE:RE:RE:RE:RE:RE:Sachs Presentation Patents - are promising and have potential! What is needed is to find someone or company that can take these promising and potential patents and use them in a way that solves the problem with AD. Having a patent doesn't solve anything, it's like redesigning a mousetrap, but most rely on the cheapest and most effective mouse trap, the snap trap. Patents don't make you money or attain succes until they find a use that can prove to be succesful and fruitful. 
I have shares in another company that continues to spit out patents (QNC), but until someone finds a use for these patents that changes lives, their not worth the paper they are written on. But that's the crux of these types of speculations, it takes time and money to develop patents and one day someone will find use for even one of the patents in an experiment and volia, we all find success. This is all ground breaking experimental medical technology, the rest of the word now needs to catch up, much like Henrysc. But don't discount what individuals have to say, as many still revert back to what they know (comfortable) rather than whats in the future.
Bullboard Posts